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Abstract
Introduction—No study has examined how the relationship between polycystic ovary syndrome 
(PCOS) and atherosclerotic cardiovascular diseases (aCVD), of ischemic stroke (ISCH), acute 
myocardial infarction (AMI), and peripheral vascular disease (PAD), differ in the presence of 
venous thromboembolism (VTE).
Materials and methods—We performed a cross-sectional analysis using Truven Health 
Analytics MarketScan® Commercial databases from 2004–2011. The association between women 
aged 18–64 years with and without PCOS, and aCVD was assessed using VTE-stratified 
multivariable logistic regression models.
Results—Overall, women with PCOS were more likely to have aCVD, (aOR, 1.27; 95% CI, 
1.10–1.46) especially ISCH (aOR, 1.56; 95% CI, 1.30–1.88), than women without PCOS. When 
stratified by VTE status, women with PCOS and a VTE diagnosis had a decreased odds of having 
any aCVD (aOR 0.67; 95% CI, 0.46–0.98), and VTE diagnosis more often preceded the 
occurrence of ISCH and AMI among women with PCOS compared with women without PCOS.
Conclusions—Overall, women with PCOS were more likely to have aCVD, with stroke being 
the most prevalent manifestation. Although VTE often occurred before any aCVD, it appeared to 
have an inverse association with the development of ISCH, AMI, and PAD among women with 
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PCOS, suggesting that aggressively treating VTE or aCVD early may limit the chances of 
developing the other thrombogenic condition among women with PCOS.
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1. Introduction
Atherosclerosis is a chronic and progressive disease that develops early in life [1]. As 
atherosclerosis progresses, it can lead to the occurrence of cardiovascular events or 
atherosclerotic cardiovascular diseases (aCVD) the manifestations of which include acute 
myocardial infarction (AMI), ischemic stroke (ISCH), coronary heart disease, and peripheral 
vascular disease (PAD) [2,3].
From 2008–2010, the average rate of death attributable to all aCVD was 242.4 per 100,000 
[4]. Thus, more than 2200 Americans died of aCVD each day, an average of 1 death every 
39 seconds. Similarly, mortality data from2010 indicated that stroke accounted for 
approximately 1 of every 19 deaths in the U.S. [4]
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting 
women of reproductive age [5,6]. Its exact etiology is unknown, but it is characterized by a 
heterogeneous presentation of hyperandrogenism, ovulatory dysfunction, and polycystic 
ovaries. PCOS has been associated with increased risk for hypertension and metabolic 
abnormalities (e.g. low levels of high-density lipoprotein cholesterol) [7–10] and women 
with irregular menses also have manifestations of atherosclerosis, specifically AMI and 
ISCH, at younger ages [11]. Detection of traditional aCVD risk factors and surrogate 
markers of atherosclerosis at a young age in women with PCOS puts them at an increased 
risk for development of symptomatic aCVD [7,10,12].
Studies have likewise shown an association between venous thromboembolism (VTE) and 
atherosclerosis [13,14]. For example, Prandoni et al. 2003, demonstrated a relationship 
between asymptomatic atherosclerotic lesions and spontaneous venous thrombosis of the 
legs [13].
These findings are relevant to women with PCOS because Okoroh et al. 2012 found a higher 
prevalence of VTE among women with PCOS when compared with the general population 
[15]. One could infer that women with PCOS and VTE would be at the greatest risk of 
developing the sequalae of atherosclerosis compared with women without PCOS and with 
VTE. Thus, the primary aim of this study was to determine how the association between 
PCOS and aCVD differs in the presence of VTE.
2. Material and methods
2.1. Data source
The data were derived from the 2004–2011 Truven Health Analytics MarketScan® 
Commercial databases which are longitudinal, de-identified health insurance claims data 
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from large employers and health plans across the U.S. This commercial database has met or 
exceeded requirements of the U.S. Health Insurance Portability and Accountability Act 
(HIPAA) of 1996. The MarketScan databases are de-identified and meet the criteria for a 
limited-use dataset and does not require specific patient consent for participation in the study 
[16].
2.2. Study population
Women with PCOS were defined by the presence of International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) codes for clinical hyperandrogenism 
(acne (706.0 or 706.1), alopecia (704.0x), and/or hirsutism (704.1)), ovulatory dysfunction 
(626.0, 626.1, 626.2, 626.3, 626.4, 626.5, 626.6, 626.7, 626.8, or 626.9), and/or polycystic 
ovaries (256.4). To reduce misclassification of PCOS cases, we excluded women who met 
the criteria for PCOS and one or more related conditions: adrenal hyperplasia (255.0 or 
255.9), hyperprolactinemia (253.1), or thyroid disorder (244.0, 244.1, 244.2, 244.3, 244.8, 
244.9, 242.90, or 242.91). Due to the heterogenic nature of PCOS and its complex 
presentation and definition, we also looked for the presence of associated conditions seen 
among women with PCOS (such as obesity [278.0, 278.00–278.02, 783.1, or V77.8]; 
infertility [628.0 or 628.9]; syndrome X, or metabolic syndrome, [277.7]; hypertension 
[401.x, 405.x]; thrombophilia [289.81]; and diabetes [250.x]). Diagnoses reported on 
inpatient claims were considered valid; those based solely on outpatient claims required that 
the diagnoses be reported on two or more claims that occurred more than 30 days apart.
VTE during the study period was identified using ICD-9-CMcodes for DVT (671.3x, 
671.4x, 671.5x, 671.9x, 451.11, 451.19, 451.2, 451.81, 451.9, 453.1, 453.2, 453.40–453.42, 
453.8, or 453.9), or PE (673.2x, 673.8x, 415.11, or 415.19), or both, on any inpatient or 
outpatient claim. We restricted outpatient diagnoses to those who had a filled prescription 
for an anticoagulant medication within 90 days of the diagnosis; for an inpatient diagnosis, 
only one ICD-9-CM code for DVT or PE was required.
CVD were defined by the presence of ICD-9-CM codes for ISCH (434.xx; 437.0, 437.1, 
437.9; 438.x, and V12.54), AMI (410.xx, excluding 410.x2, which is used to designate 
follow up to the initial episode) or PAD (443.9).
A unique identifier was used to track women longitudinally over the study period. We 
included women enrolled for at least 12 months prior to and after the first PCOS diagnosis. 
The first report of PCOS diagnosis was considered the index date. Those who died during 
the 12 months after the PCOS diagnosis were also included since the post-index date 
enrollment restriction would not apply. Women who were not continuously enrolled ≥12 
months prior to the index date or ≥12 months following the index date were excluded. Each 
woman with PCOS was exactly matched with two non-PCOS controls based on age at first 
PCOS diagnosis for the cases and age at first enrollment for the controls. Controls had to be 
enrolled for at least 12 continuous months. Cases and controls were restricted to women 18–
64 years of age.
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Bivariate analyses with two-tailed chi-square tests were used to compare the distribution of 
demographic and comorbid factors for women with and without PCOS. Fisher's exact P-
values were used to compare the distribution of aCVD between women with and without 
PCOS. Conditional logistic regression on age was used to assess the likelihood of aCVD 
diagnosis (ISCH, AMI and PAD) among women with and without PCOS. We stratified the 
analysis by the presence or absence of a VTE diagnosis. PCOS was diagnosed among the 
study population before VTE or aCVD was diagnosed. The final models included only those 
factors that were statistically significant at a priori significance level (P < .05) (obesity, 
diabetes, hypertension, and thrombophilia). All data were analyzed and managed using SAS 
software version 9.3 (SAS Institute Inc., Cary, NC, USA).
3. Results
The mean age of the study population was 33.4 years. Overall, there were 33 in-hospital 
deaths among women with PCOS and 99 among the controls. Women with PCOS had 
significantly higher proportions of all chronic comorbid conditions as well as thrombophilia, 
infertility, and VTE (Table 1). Of the 1224 women with PCOS and VTE, 529 (43.2%) had a 
PE. Of the 831 women without PCOS but with VTE, 310 (37.3%) had a PE. Overall, 839 
(40.8%) of the study population with VTE had a PE.
Overall, women with PCOS were more likely to have aCVD, (aOR, 1.27; 95% CI, 1.10–
1.46) especially ISCH (aOR, 1.56; 95% CI, 1.30–1.88), than women without PCOS. 
Stratification by VTE is shown in Table 2. Among women with PCOS and VTE, the 
unadjusted (OR, 0.72; 95% CI, 0.50–1.04) and adjusted (aOR, 0.67; 95% CI, 0.46–0.98) 
odds of having any aCVD was decreased compared with women without PCOS and with 
VTE (Table 2). In contrast, women with PCOS and without VTE were more likely to have 
aCVD diagnosis compared with women without PCOS and without VTE even after 
adjusting for confounders (Table 2).
Timing of aCVD and VTE occurrence among the study population was also evaluated. VTE 
tended to precede the occurrence of ISCH and AMI among women with PCOS compared 
with women without PCOS (Table 3).
4. Discussion
To our knowledge, this is the first study to assess the association between PCOS and aCVD 
among women with and without VTE. We found that women with PCOS were more likely 
to have comorbid conditions such as obesity, infertility, and diabetes as well as 
atherosclerosis manifestations of stroke, myocardial infarction, and peripheral vascular 
disease compared with women without PCOS. We also found that ischemic stroke was the 
most likely atherosclerotic manifestation present among this cohort. This finding is similar 
to the meta-analysis done by de Groot et al. [17] They found a pooled relative risk for 
coronary heart disease/stroke of 2.02 for women with PCOS compared with those without 
PCOS.
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When stratified by VTE status, we found VTE possibly acting as an effect modifier between 
aCVD and PCOS where its presence among women with PCOS appeared protective to the 
occurrence of aCVD. Studies have shown an inverse association between sub-clinical 
atherosclerosis and future VTE development [18,19]. It is possible that this inverse 
association may also occur for future development of atherosclerosis after a VTE 
occurrence. Another plausible reason for our findings is that in situations where VTE 
occurred before aCVD, the common prothrombotic triggers that both entities share such as 
thrombogenesis and endothelial damage may have been modified with lifestyle changes 
(e.g., weight loss) and/or medications (e.g., statins)—thereby decreasing the occurrence of 
the counterpart disease [13,20]. For example, Chae et al. 2014 found that when angiotensin 
receptor blockers were given to people who had developed MI or ISCH their chance of 
developing VTE was reduced [21].
The major strength of this study is in the use of a database that includes a large proportion of 
the privately-insured U.S. population. Also, the group studied was geographically diverse 
and included women seen both in an inpatient and an outpatient setting, which offers a better 
estimate of the prevalence of aCVD, VTE, and PCOS.
4.1. Limitations
Claims databases are comprised of data used for billing rather than for diagnostic purposes, 
so misclassification of cases may occur due to incomplete or inaccurate coding. To handle 
misclassification, we applied a restriction to how VTE and aCVD were defined and used an 
algorithm to define PCOS.
We could not report on the racial makeup of our study population due to lack of 
demographic information. Also, we did not control for concurrent medications use, such as 
anticoagulants which may have influenced the protective association we found. As noted 
earlier, medications use such as statins or angiotensin receptor blockers can improve the 
likelihood of developing a related thromobogenic condition; it is possible that not 
controlling for the medication gave us the inverse association seen in this study. In addition, 
our study only included women less than 65 years which precluded evaluation of aCVD 
among women whose disease manifests later in life.
5. Conclusion
Our findings add to the limited literature on the relationship between PCOS, VTE and 
atherosclerosis manifestations such as AMI and stroke. While several studies [8,9,11,22–24] 
have shown that women with PCOS are more prone to arterial thrombosis, we show here 
that the story may be more complex when we look at how these three thrombogenic 
conditions interact with each other. We acknowledge that our findings should be interpreted 
with caution and the relationship between PCOS and aCVD in the setting of VTE presence 
should be further evaluated since our data were limited and obtained from administrative 
claims.
Atherosclerotic manifestations such as ischemic stroke and myocardial infarction have been 
shown to have a link to VTE, but how PCOS changes this link is unclear. We see that the 
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presence of VTE among women with PCOS may have an inverse association with the 
development of atherosclerotic manifestations. Prospective studies will be needed to verify 
this finding. The implication of our study for clinicians is that aggressive treatment for 
women with PCOS and venous thromboembolism and women with PCOS and 
atherosclerotic manifestations may in turn limit their chance of developing the opposite 
thrombogenic condition in the future.
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